Written by: Blaine Van Leuven, MS, MBA, RAC
Executive Director, Regulatory and Strategic Development
With the passage of a new spending bill, federal agencies — including the U.S. Food and Drug Administration (FDA) — are resuming normal operations after the October – November 2025 shutdown. While critical FDA review work continued under carryover user fees, the freeze on new submissions and limited communications created operational gaps.
As FDA staff return, sponsors must carefully manage regulatory activities to stay on track amid backlogs and shifting timelines.
1. FDA Operations Resume — But Expect a Transition Period
Key points:
- The FDA can again legally accept new submissions and user-fee payments.
- Furloughed staff are returning; inspections and policy work are restarting.
- Backlogs will take time to clear — early bottlenecks are likely.
What sponsors should do:
- File new submissions immediately (NDAs, BLAs, ANDAs). The prior freeze is lifted, and FDA submission portals are actively accepting new marketing authorization applications again.
- Verify payment status: User-fee payments (PDUFA, GDUFA, BsUFA) are now due; ensure payment confirmation to start review clocks.
- Expect gradual normalization: FDA divisions are rebalancing workloads and reassigning staff — review timing may lag.
- Monitor review clocks: Timelines resume where paused; clarify whether your submission’s target dates still apply.
Practical tip: Build a 2–4 week cushion into regulatory milestones while FDA clears its post-shutdown queue.
2. Anticipate Backlogs and Slower Responses
Reality check:
- The FDA warned of “backlogs” as submissions flood in post-reopening.
- Dozens of NDAs/BLAs delayed during the shutdown will now be entering review simultaneously.
Possible impacts:
- Longer intake times and slower review initiation.
- Delays in scheduling Type B/C meetings or advisory committees.
- Temporary slowdown in inspection scheduling.
How to mitigate:
- Submit early: Don’t wait for “normal” operations — get in the queue.
- Stay proactive: Regularly follow up with project managers for updates.
- Document everything: Track communications to avoid confusion as FDA catches up.
- Reconfirm key dates: If your PDUFA or meeting date falls soon, request confirmation that it remains unchanged.
Practical tip: For ongoing submissions, allocate extra time for agency correspondence and avoid setting public milestones until FDA timing stabilizes.
3. NDA/BLA Submissions and Approvals
Post-shutdown restart:
- Marketing applications (NDAs, BLAs) can now be submitted and reviewed.
- User fees must be paid immediately for submissions to be considered “received.”
- Submissions sent during the shutdown should now be re-logged with new receipt dates.
Action checklist:
- Confirm payment posting and receipt acknowledgment — this starts the PDUFA review clock.
- Contact FDA to verify that your submission has been processed and assigned.
- Adjust development timelines: Each month of shutdown roughly shifts approvals and milestones by the same duration.
- Update internal/external stakeholders on revised expectations for reviews, approvals, and launch schedules.
Expect triaging:
- FDA will prioritize applications nearing decision dates or addressing urgent public health needs.
- Less urgent applications may face longer response cycles or postponed meetings.
For applications already under review:
- Check in with your Regulatory Project Manager about any delays in labeling negotiations, inspections, or advisory meetings.
- Confirm your target action date and whether any new information is needed.
Practical tip: Be strategic – if your submission isn’t time-sensitive, waiting a few weeks could yield smoother review processing once backlogs ease.
4. Meetings and Communications
Re-engagement essentials:
- Meetings postponed during the shutdown will be rescheduled
- New meeting requests will face longer lead times due to heavy scheduling demand.
For previously scheduled meetings:
- Immediately confirm new dates or formats with your Regulatory Project Manager.
- Be flexible — some meetings may move out several weeks as FDA reprioritizes.
- For urgent discussions , communicate importance clearly but professionally.
For new meeting requests:
- Submit early and don’t wait; assume scheduling may exceed standard windows.
- Prepare complete, focused briefing packages — well-prepared materials enable more efficient review and reduce back-and-forth.
- Expect slower response to general inquiries as staff clear inboxes.
Practical tip: Track every inquiry or submission from the shutdown period and resend critical items if unanswered — politely flag them as follow-ups.
5. Inspections and Compliance Restart
What’s changing:
- During the shutdown, FDA limited inspections to mission-critical cases (e.g., imminent health risks).
- Now, all inspectional activities — GCP, GMP, PAI — are resuming.
Sponsors should:
- Prepare for short-notice inspections as FDA reschedules backlog visits.
- Contact your FDA district office or project lead if you had a pending inspection.
- Maintain inspection readiness: conduct internal audits, refresh SOP training, and ensure documentation is complete.
- Address any pending compliance inquiries immediately now that FDA oversight is fully active again.
For upcoming approvals:
- Confirm pre-approval inspection (PAI) timelines — delays could impact your PDUFA or GDUFA date.
- Discuss alternatives (e.g., remote interactive evaluations or record reviews) if timing becomes critical.
- Continue robust pharmacovigilance and quality monitoring — compliance requirements never paused.
Practical tip: Treat reopening as full enforcement resumption — expect scrutiny, not leniency.
6. Managing Global Impact
Global coordination matters:
- EU, Japan, and other regulatory bodies were unaffected – global programs likely advanced while U.S. activities paused.
- Result: potential timeline misalignment between FDA and other regulators.
To realign:
- Adjust global launch or submission sequencing to reflect U.S. review delays.
- Ensure consistent data packages across regions — what’s reviewed abroad may soon be questioned by FDA.
- Communicate updates to partners about any new U.S. timelines.
Practical tip: Keep global regulatory teams in sync — FDA’s reopening should trigger an updated integrated development plan across all regions.
7. Moving Forward with Vigilance and Adaptability
Bottom line:
- The reopening marks a return to business, but with heavier workloads and uneven recovery across divisions.
- Sponsors that plan proactively and communicate clearly will minimize disruptions.
Action summary:
- Reconfirm all timelines, milestones, and meeting schedules.
- File new submissions promptly and verify receipt/payment.
- Maintain inspection readiness and compliance vigilance.
- Anticipate longer response times and plan internal milestones conservatively.
- Keep stakeholders informed and adjust global plans as needed.
- Watch for new FDA guidance clarifying post-shutdown priorities.
Practical tip: Treat the post-shutdown period as a reset. Reaffirm compliance, strengthen communication, and reforecast development timelines based on updated FDA activity levels.
Final Thought
A government shutdown is a stress test for regulatory resilience. Now that the FDA is open again, sponsors who stay disciplined, compliant, communicative, and flexible will navigate the post-shutdown environment successfully. Vigilance, adaptability, and proactive engagement are key to keeping programs on track through the recovery phase and beyond.
Contact us today to ensure your clinical and regulatory strategies stay aligned as the FDA resumes full operations.